MARK ESCHE: Open Payments
NPI 1174622740 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,739 in 149 payments from 14 companies in 2025. Trend: 2023 $2,650 · 2024 $2,347 · 2025 $2,739
Food & beverage: $2,737Education: $1
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 42 | $722 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $497 |
| Otsuka America Pharmaceutical, Inc. | 18 | $357 |
| ABBVIE INC. | 20 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $187 |
| Axsome Therapeutics, Inc. | 8 | $173 |
| Lundbeck LLC | 7 | $133 |
| Neurocrine BioSciences, Inc. | 5 | $95 |
| Collegium Pharmaceutical, Inc. | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
Products named: ARISTADA, CAPLYTA, REXULTI, VRAYLAR, TRINTELLIX, Auvelity, ABILIFY ASIMTUFII, INGREZZA.
Industry payments across TX — which companies pay providers there.
